Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

被引:484
作者
Fracanzani, Anna Ludovica [1 ]
Valenti, Luca [1 ]
Bugianesi, Elisabetta [2 ]
Andreoletti, Marco [3 ]
Colli, Agostino [3 ]
Vanni, Ester [2 ]
Bertelli, Cristina [1 ]
Fatta, Erika [1 ]
Bignamini, Daniela [1 ]
Marchesini, Giulio [4 ]
Fargion, Silvia [1 ]
机构
[1] Univ Milan, Hosp Maggiore Policlin, Sci Inst Recovery & Cure Fdn IRCCS, Dept Internal Med, Milan, Italy
[2] Univ Turin, Div Gastroenterol, Turin, Italy
[3] Hosp Manzoni Lecco, Dept Internal Med, Lecce, Italy
[4] Univ Alma Mater Studiorum, Dept Med, Bologna, Italy
关键词
D O I
10.1002/hep.22429
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
It is uncertain whether patients with nonalcoholic fatty liver disease (NAFLD) and normal alanine aminotransferase (ALT) have a milder disease and should undergo liver biopsy. We reviewed the histological data of 458 Italian patients with NAFLD in whom liver biopsy was indicated by altered liver enzymes (395 cases, 86%), or persistently elevated ferritin or long-lasting severe steatosis (63 cases). Factors associated with nonalcoholic steatohepatitis (NASH) and fibrosis it 2 were identified by multivariate analysis. Patients with normal ALT were significantly older, had lower body mass index, fasting triglycerides, insulin resistance according to homeostasis model assessment (HOMA-IR), ALT, and gamma-glutamyltransferase, but a higher prevalence of hypertension. NASH was diagnosed in 59% and 74% of the patients with normal and increased ALT, respectively (P = 0.01). In the overall series of patients, NASH was independently predicted by ALT (odds ratio [OR], 1.11; 95% confidence interval [CI], 1.04-1.19 per 10-IU/mL increase) and diabetes (OR, 1.5; 95% CI, 1.1-2.0). The same variables were selected in patients with increased ALT, whereas in those with normal ALT, HOMA-IR and ALT were independent predictors. Severe fibrosis was independently predicted by serum ferritin (OR, 1.04; 95% CI, 1.001-1.08 per 50-ng/mL increase), ALT (OR, 1.07; 95% CI, 1.02-1.14), and diabetes (OR, 1.8; 95% CI, 1.4-2-3) in the overall series, serum ferritin and diabetes in those with increased ALT, and only HOMA-IR (OR, 1.97; 95% CI, 1.2-3.7) in patients with normal ALT. Conclusion: Normal ALT is not a valuable criterion to exclude patients from liver biopsy. Alterations in glucose metabolism and insulin resistance in subjects with normal ALT should also be considered in the selection of NAFLD cases for histological assessment of disease severity and progression.
引用
收藏
页码:792 / 798
页数:7
相关论文
共 33 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]  
Amarapurka D N, 2006, Ann Hepatol, V5, P30
[3]   Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease [J].
Angelico, F ;
Del Ben, M ;
Conti, R ;
Francioso, S ;
Feole, K ;
Fiorello, S ;
Cavallo, MG ;
Zalunardo, B ;
Lirussi, F ;
Alessandri, C ;
Violi, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1578-1582
[4]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[5]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[6]   Carotid atherosclerosis and coronary heart disease in the metabolic syndrome - Prospective data from the Bruneck Study [J].
Bonora, E ;
Kiechl, S ;
Willeit, J ;
Oberhollenzer, F ;
Egger, G ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2003, 26 (04) :1251-1257
[7]   Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions [J].
Brunt, EM ;
Janney, CG ;
Di Bisceglie, AM ;
Neuschwander-Tetri, BA ;
Bacon, BR .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (09) :2467-2474
[8]   Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma [J].
Bugianesi, E ;
Leone, N ;
Vanni, E ;
Marchesini, G ;
Brunello, F ;
Carucci, P ;
Musso, A ;
De Paolis, P ;
Capussotti, L ;
Salizzoni, M ;
Rizzetto, M .
GASTROENTEROLOGY, 2002, 123 (01) :134-140
[9]   Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease [J].
Caldwell, SH ;
Oelsner, DH ;
Iezzoni, JC ;
Hespenheide, EE ;
Battle, EH ;
Driscoll, CJ .
HEPATOLOGY, 1999, 29 (03) :664-669
[10]   NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome [J].
Chitturi, S ;
Abeygunasekera, S ;
Farrell, GC ;
Holmes-Walker, J ;
Hui, JM ;
Fung, C ;
Karim, R ;
Lin, R ;
Samarasinghe, D ;
Liddle, C ;
Weltman, M ;
George, J .
HEPATOLOGY, 2002, 35 (02) :373-379